Adverse drug reaction reporting by patients in the Netherlands: three years of experience.
about
Focus on headache as an adverse reaction to drugsPharmacovigilance Skills, Knowledge and Attitudes in our Future Doctors - A Nationwide Study in the Netherlands.First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues.Need for involving consumers in Nepal's pharmacovigilance systemSide effects of antineoplastic and immunomodulating medications reported by European consumers.The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis.Consumer reporting of adverse events following immunization (AEFI): identifying predictors of reporting an AEFI.Motives for reporting adverse drug reactions by patient-reporters in the Netherlands.Adverse drug reactions reported by consumers for nervous system medications in Europe 2007 to 2011A nationwide medication incidents reporting system in The NetherlandsAn evaluation of knowledge, attitude, and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital.Consumer Narratives in ADR Reporting: An Important Aspect of Public Health? Experiences from Reports to a Swedish Consumer OrganizationThe value of patient reporting to the pharmacovigilance system: a systematic review.A qualitative exploration of the major challenges facing pharmacovigilance in Saudi Arabia.Evaluation of an interactive program for preventing adverse drug events in primary care: study protocol of the InPAct cluster randomised stepped wedge trial.Systematic collection of patient-reported adverse drug reactions: a path to patient-centred pharmacovigilance.Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an examplePharmacovigilance Programme of India: Recent developments and future perspectivesPatient knowledge on reporting adverse drug reactions in Poland.Web-based intensive monitoring: from passive to active drug surveillance.Safety aspects of antiepileptic drugs--focus on pharmacovigilance.Experiences with adverse drug reaction reporting by patients: an 11-country survey.Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review.Adverse drug reaction reporting by patients: an overview of fifty countries.Issues in online patient self-reporting of health status.ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems.Informativeness of patient initial reports of adverse drug reactions. Can it be improved by a pharmacovigilance centre?Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance.Patients' motives for participating in active post-marketing surveillance.Public confidence in ADR identification and their views on ADRreporting: mixed methods study.Survey of patients' experiences and their certainty of suspected adverse drug reactions.How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme.Consumers' reports of suspected adverse drug reactions volunteered to a consumer magazine.Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy.Effect of pharmacist involvement on patient reporting of adverse drug reactions: first Italian study.Adverse drug reactions in children reported by European consumers from 2007 to 2011.Pharmacovigilance for a revolving world: prospects of patient-generated data on the internet.How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician- and patient-reported adverse events in patients with rheumatoid arthritis observed in the German biologics register.Intensive monitoring of pregabalin: results from an observational, Web-based, prospective cohort study in the Netherlands using patients as a source of information.
P2860
Q28483956-063D00A1-4460-4A13-8FE9-318BBECB0848Q30151585-C340B679-BF6A-4577-B0AD-2970DFB3856EQ30421150-6C866074-787B-4FE8-BD09-6FE0AE9AF8C3Q30716859-52622420-1593-4915-A653-5CB00E960BEFQ33565507-6F314606-44B0-4A72-98CD-9E4B3C14B4A3Q33827959-D8488C5B-EEBB-4A65-AEDC-E975EC257F44Q33845548-542AA6AD-5F77-40C2-A923-D9C6CB98C01AQ34033938-0AAEA791-8514-4829-AF39-4A7FA2C319F8Q34213612-575E8911-D8C2-4292-AA92-BAA8145E6FCEQ34771486-C0A5F071-AF13-47FC-873C-F2F098752CC5Q35403955-F8F48C86-2237-47B3-8FDF-CA9FBB9B647AQ35582089-4228E6DF-D814-4053-8D9E-2D9660626D91Q36015119-0CFE7C0D-981E-4B04-8156-6976B854ED58Q36112324-8A4EA55C-1C2E-4D31-9727-9A7CC95C0854Q36185006-29F3A501-AE98-46C8-99D9-0E02FC4AC1A9Q36945547-3780B681-1103-4D72-BE1F-86A763696E27Q37045186-C394E6E5-9F5E-427F-9855-28E400AE2EB9Q37201698-A1F8CCD8-7696-43CA-958D-32D1E052F54EQ37501938-F9526A4D-F585-4FA4-AB0F-C1386079EF3AQ37551882-FE2D1ECB-F012-4E6F-A5B6-63FCA1D1FDBCQ37946924-FF00A6DF-F406-4573-B8D9-DD7E9F589616Q37954227-08079C19-4D81-41DA-B733-2DBAB78C1866Q37965625-EBF55FBA-2135-414A-B61C-78CE42D0A05FQ38038675-60EDBC62-6504-4132-A91F-81AAB67E8ED6Q38205725-6DC71982-6B4E-422F-A76B-537186DDBB69Q38240932-046D9D6A-A27B-4CBD-A370-55BCCD2104DEQ38334927-FAD511D2-D7D4-49B8-8EC1-F8B0AC7E8A10Q39229385-7DDFF42C-D999-49C8-989E-DC82A607213BQ39538570-761EA2F7-87EC-41F2-ADBC-848AD83B46B2Q39579049-9AD84A29-4758-4E22-B189-F255A3A9DAC5Q40478509-B06F8D87-7CB5-4A71-94A6-773CF26CF63FQ41598140-36F62E2E-D5DD-466E-86C1-24EFCBC5AF2CQ42598431-C4F4C2DB-C4E2-446A-A534-2272A1FC3E57Q42905448-148A4AD7-DB20-4022-AAFF-B041757CBF9DQ44041568-FC2B57AD-2DD4-4DDE-A3FC-15CE01F903A8Q44356753-1ED52D57-9902-4E67-8DFA-8B455B831EDEQ44585310-CB39266A-D3E2-4DBD-A83C-9EB5864C6A9CQ44883574-E749F36D-A485-48ED-9B58-8D49F8068A6BQ45904376-4137DC3C-45A1-4006-9190-1423515F3899Q45921748-E6F330CF-E3EE-4795-8265-6B2B013BA624
P2860
Adverse drug reaction reporting by patients in the Netherlands: three years of experience.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Adverse drug reaction reportin ...... ds: three years of experience.
@en
Adverse drug reaction reportin ...... ds: three years of experience.
@nl
type
label
Adverse drug reaction reportin ...... ds: three years of experience.
@en
Adverse drug reaction reportin ...... ds: three years of experience.
@nl
prefLabel
Adverse drug reaction reportin ...... ds: three years of experience.
@en
Adverse drug reaction reportin ...... ds: three years of experience.
@nl
P2093
P1433
P1476
Adverse drug reaction reportin ...... ds: three years of experience.
@en
P2093
Anneke Passier
Florence van Hunsel
Joyce de Langen
Kees van Grootheest
Lolkje de Jong-van den Berg
P304
P356
10.2165/00002018-200831060-00006
P577
2008-01-01T00:00:00Z
P5875
P6179
1040788655